| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Patient-derived tumor xenograft (PDX) animal model is one of a screening platform in the world, which can be used to replace patients and provide cancer treatment in animals by transplanting patient-derived tumors removed from patients directly into immunocompromised animals. The purpose of this study is to increase the efficacy of transarterial chemo-infusion by establishing the PDX model in rats. We conducted two phase studies. (1) To create a liver metastasis model in which fresh patient-derived primary pancreatic cancer tumors removed by surgery are directly transplanted into the liver of immunodeficient rats; (2) To perform interventional radiology (IVR) treatments such as transarterial chemo-infusion in the model. We completined experiment 1. The primary pancreatic cancer tissue was able to be transplanted into the liver of rats. Next, we are currently conducting experiments to determine the anti-tumor effects of IVR treatment.
|
